$3.36
0.30% today
Nasdaq, Aug 12, 04:16 pm CET
ISIN
US00972D1054
Symbol
AKBA

Akebia Therapeutics, Inc. Stock price

$3.35
-0.58 14.76% 1M
+1.25 59.52% 6M
+1.45 76.32% YTD
+2.12 172.36% 1Y
+2.95 740.44% 3Y
-6.93 67.41% 5Y
-6.09 64.51% 10Y
-23.35 87.45% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
-0.07 2.05%
ISIN
US00972D1054
Symbol
AKBA
Industry

Key metrics

Basic
Market capitalization
$888.2m
Enterprise Value
$821.4m
Net debt
positive
Cash
$113.4m
Shares outstanding
261.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
4.8 | 4.3
EV/Sales
4.4 | 4.0
EV/FCF
negative
P/B
36.1
Financial Health
Equity Ratio
-22.3%
Return on Equity
141.1%
ROCE
-8.3%
ROIC
-
Debt/Equity
1.9
Financials (TTM | estimate)
Revenue
$184.9m | $205.0m
EBITDA
$8.8m | -
EBIT
$-18.2m | $13.1m
Net Income
$-45.3m | $-17.1m
Free Cash Flow
$-34.9m
Growth (TTM | estimate)
Revenue
-1.2% | 28.0%
EBITDA
479.6% | -
EBIT
47.2% | 128.3%
Net Income
-5.2% | 75.4%
Free Cash Flow
-37.9%
Margin (TTM | estimate)
Gross
82.9%
EBITDA
4.8% | -
EBIT
-9.9%
Net
-24.5% | -8.3%
Free Cash Flow
-18.9%
More
EPS
$-0.2
FCF per Share
$-0.1
Short interest
9.8%
Employees
181
Rev per Employee
$880.0k
Show more

Is Akebia Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Akebia Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Akebia Therapeutics, Inc. forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a Akebia Therapeutics, Inc. forecast:

Buy
91%
Hold
9%

Financial data from Akebia Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
185 185
1% 1%
100%
- Direct Costs 32 32
1% 1%
17%
153 153
1% 1%
83%
- Selling and Administrative Expenses 107 107
6% 6%
58%
- Research and Development Expense 38 38
29% 29%
20%
8.81 8.81
480% 480%
5%
- Depreciation and Amortization 27 27
25% 25%
15%
EBIT (Operating Income) EBIT -18 -18
47% 47%
-10%
Net Profit -45 -45
5% 5%
-25%

In millions USD.

Don't miss a Thing! We will send you all news about Akebia Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Akebia Therapeutics, Inc. Stock News

Neutral
Seeking Alpha
5 days ago
Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Erik John Ostrowski - Chief Business Officer, Senior VP, CFO & Treasurer John P. Butler - CEO, President & Director Mercedes Carrasco - Senior Director of Investor & Corporate Communications Nicholas Grund - Senior VP & Chief Commercial Officer Conference Call Participants Ju...
Positive
The Motley Fool
5 days ago
Akebia (AKBA) Q2 Revenue Jumps 43%
Neutral
GlobeNewsWire
5 days ago
Continued Vafseo® (vadadustat) growth with Q2 2025 net product revenues increasing to $13.3 million ; Total Q2 2025 net product revenues increased to $60.5 million DaVita physicians are expected to begin treating patients with Vafseo in August 2025 as part of an operational pilot at 100+ DaVita dialysis clinics Patient enrollment completed in VOICE, a collaborative clinical trial of Vafseo cond...
More Akebia Therapeutics, Inc. News

Company Profile

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Head office United States
CEO John Butler
Employees 181
Founded 2007
Website akebia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today